Fig. 3.
Fig. 3. Specific binding of [125 I]Tat to monocytes and curve displacement with cold rTat and VEGF-A165 . (A) Specific [125I]Tat binding curve to monocyte at equilibrium and Schatchard analysis. For specific binding studies of Tat, human monocytes (1 × 106/ 0.2 mL of binding buffer) were incubated with increasing concentrations of [125I]Tat in the presence of a 100-fold excess of unlabeled ligand at 22°C for 120 minutes. At the end of incubation, cell suspension were overlayered on 0.5 mL of dibutylphtalate and centrifuged for 10 minutes at 13,000g, and the pellet was solubilized with 2% SDS in PBS was counted in a γ counter. (B) Ligand displacement curve at equilibrium of [125I]Tat binding to monocytes by rTat and VEGF-A165 . Human monocytes (1 × 106) were treated in the same way as in (A) with 0.7 pmol of [125I] without or with the indicated concentrations of unlabeled rTat (○) or VEGF-A165 (•). Each experiment was repeated at least three times.

Specific binding of [125 I]Tat to monocytes and curve displacement with cold rTat and VEGF-A165 . (A) Specific [125I]Tat binding curve to monocyte at equilibrium and Schatchard analysis. For specific binding studies of Tat, human monocytes (1 × 106/ 0.2 mL of binding buffer) were incubated with increasing concentrations of [125I]Tat in the presence of a 100-fold excess of unlabeled ligand at 22°C for 120 minutes. At the end of incubation, cell suspension were overlayered on 0.5 mL of dibutylphtalate and centrifuged for 10 minutes at 13,000g, and the pellet was solubilized with 2% SDS in PBS was counted in a γ counter. (B) Ligand displacement curve at equilibrium of [125I]Tat binding to monocytes by rTat and VEGF-A165 . Human monocytes (1 × 106) were treated in the same way as in (A) with 0.7 pmol of [125I] without or with the indicated concentrations of unlabeled rTat (○) or VEGF-A165 (•). Each experiment was repeated at least three times.

Close Modal

or Create an Account

Close Modal
Close Modal